Dr. Reddy's Laboratories slides Friday, underperforms market
Dr. Reddy's Laboratories Ltd. closed 18.89% below its 52-week high of 1,420.20 rupees, which the company reached on August ...
Dr. Reddy's Laboratories rises Thursday, outperforms market
Dr. Reddy's Laboratories Ltd. closed 17.55% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...
Allspring Global Investments Holdings LLC Acquires 427,573 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)
Allspring Global Investments Holdings LLC grew its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by ...
ETF Daily News4d
Savant Capital LLC Takes Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)
View Our Latest Report on Dr. Reddy’s Laboratories Dr. Reddy’s Laboratories Trading Down 0.3 % NYSE RDY opened at $13.57 on Wednesday. The company has a current ratio of 1.92, a quick ratio of ...
Hosted on MSN18d
Dr. Reddy’s Laboratories Engages with Investors in Upcoming Conferences
An announcement from Dr Reddy’s Laboratories ( ($RDY) ) is now available. On February 4, 2025, Dr. Reddy’s Laboratories announced its ...
Hosted on MSN18d
Dr. Reddy’s Laboratories to Engage with Investors in Mumbai Conference
Dr Reddy’s Laboratories ( ($RDY) ) has shared an update. On February 4, 2025, Dr. Reddy’s Laboratories announced its participation in an investor ...
Mint29d
Dr Reddy’s Laboratories share price declines 6% post Q3 results: Should you buy, sell or hold?
Stock Market Today: Dr Reddy's Laboratories share price declined more than 6% in the morning trades on Friday post-Q3 results that were announced after the market hours of Thursday. On Thursday ...
Business Insider27d
Barclays Reaffirms Their Buy Rating on Dr Reddy’s Laboratories (RDY)
Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of $17.00. The company’s shares closed last Friday at ...
Benzinga.com14d
Dr. Reddy's Laboratories Reports Strong Q3 & 9MFY25 Financial Results with Strategic Growth Trajectory
Dr. Reddy's Laboratories DRREDDY RDY has delivered a set of financial results. For the third quarter (Q3FY25) and the nine months (9MFY25) ending December 31, 2024, the company showcased robust ...
moneycontrol.com29d
Reduce Dr. Reddy's Laboratories; target of Rs 1335: Prabhudas Lilladher
Dr. Reddy’s (DRRD) Q3FY25 EBITDA was below our estimate. The base business margins and US sales ex of gRevlimid and one offs continued to remain weak. We have scale up base business margins from ...
Mint29d
Indian drugmaker Dr Reddy’s shares slide after Q3 profit miss
(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine months, after missing its third-quarter profit estimates on lower sales ...
Business Wire16d
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY ...